Replies to post #261641 on Amarin Corp Plc (AMRN)

[amarininvestor]

Not only that, she accepts Kurabayashi study as valid (even when the patients were given a lipid modifying agent) as part of the obviousness case regarding ApoB, when it clearly this is both a group of patients below 500mg/dl and taking a confounding therapy and then rejects REDUCE-IT as insufficiently linked to the case on the secondary considerations because the patients on that group were below 500mg/dl and represent a different group (even when a small group of patients in reduce-it were above 500mg/dl)

So many issues on this ruling....